Nvidia-backed Iambic Therapeutics files for U.S. IPO
Iambic Therapeutics, backed by NVIDIA, filed for a U.S. initial public offering and plans to list on Nasdaq under the ticker IAM.
Iambic Therapeutics, backed by Nvidia (NVDA), is moving toward the public markets, offering investors a new way to trade the intersection of artificial intelligence and drug discovery. S. initial public offering and plans to list on Nasdaq under the ticker IAM.